Efficient T-cell stimulation and proliferation in response to specific antigens is a goal of immunotherapy against infectious disease and cancer. Manipulation of this response can be accomplished by adoptive immunotherapy involving the infusion of antigen-specific T-cell populations expanded ex vivo with antigen presenting cells. We mimicked physiological antigen presentation on a biodegradable microparticle constructed from poly(lactideco-glycolide) (PLGA), a polymer system whose safety has been established for use in humans. These particles present a high density of adaptor elements for attaching both recognition ligands and co-stimulatory ligands to a biodegradable core encapsulating the cytokine interleukin-2 (IL-2). We demonstrate the utility of this system in efficient polyclonal and antigen-specific T-cell stimulation and expansion, showing that sustained release of IL-2 in the vicinity of T-cell contacts dramatically improves the stimulatory capacity of these acellular systems, as compared to the effect of exogenous addition of cytokine. This results in a 45-fold enhancement in T-cell expansion. In addition, this mode of antigen presentation skews the expansion toward the CD8 + T-cell phenotype. This comprehensive acellular platform, capable of delivering recognition, costimulatory, and cytokine signals, represents a promising new technology for artificial antigen presentation.
IntroductIon
Adoptive immunotherapy is a procedure whereby lymphocytes are expanded ex vivo and reinfused back into the body to enhance therapy against viral infection, 1,2 autoimmune disease, 3, 4 or cancer. [5] [6] [7] While natural antigen-presenting cells (APCs), notably dendritic cells (DCs), are the most potent in initiating immune responses, their use in ex vivo stimulation of antigen-specific immune responses in clinical settings involving adoptive immunotherapy has been limited because of issues related to the quality, expense, and time involved in their isolation and culture. 8 Because T-cell restriction necessitates the use of autologous dendritic cells, customized isolation must be carried out for individual patients, thereby limiting the general application of this therapy. In order to address this issue, artificial APCs (aAPCs) based on cellular and acellular systems have been proposed and tested. 8, 9 Cellular aAPCs have been created from human leukemia cell lines, 10, 11 insect cells, [12] [13] [14] and mouse fibroblasts. 15, 16 Although physiological in nature, these systems may require genetic modifications in order to effectively present antigens, and may carry the risk for potential infection or tumorigenicity. Acellular approaches use micron-size latex, polyglycolide, or magnetic beads 8, [17] [18] [19] and lipid-based vesicles. [20] [21] [22] While these platforms may eliminate the risk of infection by utilizing synthetic constructs, many lack biocompatibility and the physiological features that can enhance antigen presentation. 9 In addition, some acellular platforms, such as magnetic beads, skew expansion toward the CD4 + T-cell phenotype, with minimal effects on the CD8 + T-cell subset 8 which is an important population for cancer immunotherapy.
T-cell responses are mediated by the signals received from APCs. 23 Current approaches toward engineering of aAPCs exploit both recognition signals and co-stimulatory signals in the form of specific peptide-major histocompatibility complex (peptide-MHC) complexes or antibodies that crosslink the T-cell CD3 complex (recognition) and CD28 (co-stimulation). A third signal can be provided by cytokines, which are secreted by activated APCs after T-cell encounters, and which impact expansion, survival, effector function, and memory of stimulated T cells. [23] [24] [25] None of the current aAPC platforms takes advantage of this paracrine mode of cytokine delivery although it is a central component of physiological T-cell-APC signaling. 23 Typically, cytokines are added to cultures exogenously and administered systemically to patients after reinfusion of T cells; however, such systemic administration can be associated with acute toxicity. 24 In addition, cytokine withdrawal can occur when T cells are transferred from ex vivo culture in high-concentration interleukin-2 (IL-2) to a patient, leading to failures in T-cell persistence in vivo. 26 Currently there are no aAPC technologies that incorporate all three signals in a safe, readyto-use system that is rapidly modifiable for antigen-specific or polyclonal T-cell expansion. This is a clear limitation in design, and we seek to address it by the approach we report here.
We demonstrate that the features of an ideal APC, as described earlier, can be incorporated into a biodegradable microparticle that facilitates efficient stimulation of T cells. The biodegradability of this system allows for encapsulation and local release of cytokines, thus mimicking the natural mode of action of this important third signal. We show that paracrine release offers advantages over the traditional approach of adding exogenous cytokine. The ability of this system to release cytokines in a sustained manner, coupled with the ease of attaching multiple ligands, results in a durable, artificial antigen-presenting system for T-cell expansion. These aAPCs represent a true "off-the-shelf, " flexible technology that is amenable both to long-term storage and to immediate use.
results

Fabrication of PlGA aAPcs
The aAPC platform is depicted in Figure 1 . Particles can be fabricated with varying diameters in the micro-to nanometer range, and are constructed from poly(lactide-co-glycolide) (PLGA), a polymer whose safety of use in humans has been established for the past 30 years. 27, 28 Immobilization of avidin on the surface of the particles is accomplished using an avidin-palmitate conjugate that associates with PLGA during particle synthesis, 29 resulting in an average avidin density of 71 µg/mg of polymer (SD = 19 µg/mg, data not shown). Micro-and nanoparticles display similar densities of avidin on a per-mass basis. The presence of avidin allows attachment of a high density of immunologically relevant biotinylated ligands whose presentation is prolonged during polymer degradation and release of encapsulated cytokines because of the preferential association of the fatty acid-avidin conjugate with the surface of the particle. 29 Biotinylated MHC dimers and antibodies for recognition and co-stimulation of T cells are coupled to aAPCs immediately before use by taking advantage of the high-affinity binding between avidin and biotin. In addition to the surface presentation of ligands, previous work with PLGA micro-and nanoparticles has demonstrated success for the delivery of small molecules and proteins, 27, 30 potentially providing an important third signal for T-cell stimulation.
Both nanoparticles and microparticles were fabricated using identical formulations. Particles were created using single emulsion (microparticles) and double emulsion (micro-and nanoparticles) techniques as earlier described, 31 and were surface-modified with avidin. 29 Scanning electron microscopy revealed particles with average diameters of 8.0 µm and 130 nm for micro-and nanoparticles, respectively (Figure 2a-d) . The particles were qualitatively visualized with T cells, and we observed stable interactions (Figure 2e and Supplementary Figure S1 ). The biocompatibility of untargeted aAPCs (particles without attached biotinylated ligands) was confirmed using a range of particle concentrations, and no effect on proliferation was observed (Supplementary Figure S2) . Figure S3) .
Micro
In order to assess the optimal concentration of particles to be used with T cells, aAPCs were titrated beginning at 5 mg/ml and incubated with purified CD8 + T cells from OT-I mice, a class-I © The American Society of Gene Therapy . aAPCs were fabricated using single and double emulsion techniques that allow the encapsulation of cytokines. The Avidin-palmitate conjugate was incorporated to facilitate the presentation of avidin on the particle surface. Biotinylated ligands for recognition and co-stimulation (anti-CD3, anti-CD28, and peptide-MHC complexes) were attached to aAPCs through binding to avidin presented on the aAPC. Encapsulated cytokines are released from particles in a time-dependent manner. MHC, major histocompatibility complex; PLGA, poly(lactide-co-glycolide). . Activation was assessed by measuring IL-2 levels from cell culture supernatant. We observed that optimal stimulation occurs at an intermediate aAPC concentration, beyond which T-cell IL-2 secretion declines (Figure 3) . The data were fitted to a well-established model that accounts for the biophysical aspects of this trend, 33 and model fit parameters are given in Supplementary Table S1 . This model predicts that activation of immune cells by multivalent ligands will exhibit a bell-shaped concentration dependence curve, because of receptor aggregation on the surface of the cells. 33, 34 In this model, the decreased response at high ligand concentrations is a result of less efficient aggregation between ligands and receptors. Earlier work has reported similar trends showing symmetric, bell-shaped, nonsaturating concentration dependence curves when utilizing multivalent constructs for the stimulation of T cells. 20, 34, 35 Both micro-and nanoparticles exhibit bell-shaped curves, but the stimulation maximum for microparticle aAPCs occurs at a lower concentration of constructs than the maximal response from nanoparticle aAPCs (Figure 3) . In addition to the shift in optimal concentration, peak levels of IL-2 secretion were much higher in response to microparticle aAPCs when compared with nanoparticle aAPCs. These findings are supported by those of previous reports, demonstrating that micron-sized particles, which are close in size to T cells, provide optimal T-cell stimulation. 36 From the peak of the curve in Figure 3 , we deduced that for this aAPC system, a ratio of 1:8 (particles:T cells) is optimal for stimulation.
Addition of co-stimulatory signals to aAPcs further increases t-cell stimulation aAPCs were prepared with anti-CD28 and anti-CD3 for polyclonal activation, or with SIIN K b and anti-C28 for antigen-specific activation. IL-2 and interferon-γ (IFN-γ) secretion as well as T-cell proliferation were assessed in order to determine activation and function of the cells. In the absence of co-stimulation, C57BL/6 (B6) T cells secreted minimal IL-2 and IFN-γ and failed to proliferate significantly (Figure 4a-c) . The addition of anti-CD28 induced robust cytokine secretion and enhanced proliferation. Similarly, antigen-specific stimulation was increased by a fourfold enhancement in IL-2 secretion after the addition of co-stimulatory molecules to the aAPC surface (Figure 4d ). These results are consistent with earlier studies that used polystyrene latex microspheres for T-cell stimulation, 37 and show that incorporation of co-stimulatory molecules on the particle surface improves T-cell expansion.
controlled release of rhIl-2 from biodegradable aAPcs enhances t-cell expansion in a concentration-dependent manner
The delivery of IL-2 increases the viability and proliferative capacity of T cells. 38 A distinct advantage of the current platform is its ability to encapsulate and release cytokines such as IL-2 in a sustained fashion. The release of the cytokine can be controlled by varying the particle preparation conditions. In order to demonstrate these features, recombinant human IL-2 (rhIL-2) was encapsulated in microparticles using three methods: (i) in phosphate-buffered saline (PBS) using a double emulsion waterin-oil-in-water technique (low encapsulation with burst release); (ii) as a lyophilized solid using a single emulsion solid-in-oilin-water (s/o/w) technique (medium encapsulation with burst); (iii) by first stabilizing with trehalose, a known preservation agent, 39 then encapsulating using a single emulsion s/o/w technique (high encapsulation and sustained release). In control experiments trehalose had neither a stimulatory nor an inhibitory effect on T-cell activation (Supplementary Figure S4) . The kinetics of controlled release of rhIL-2 from each type of microparticle aAPC in PBS are shown in Figure 5a . Controlled release curves were obtained from 10 mg of particles without attached biotinylated ligands. The attachment of surface ligands does not affect the release characteristics. 29 The resulting biphasic plots are typical of protein release during PLGA particle degradation and are characterized by an initial burst release followed by continual release of protein over time. 40 In order to examine the effects of varying rhIL-2 loading on T-cell stimulation, B6 splenocytes were stimulated in a polyclonal manner by aAPCs fabricated with different rhIL-2 loading ("loaded IL-2 aAPCs") presenting anti-CD3 and anti-CD28. As expected, peak stimulation was observed with lower aAPC concentrations encapsulating higher levels of rhIL-2, releasing gradually (Figure 5b) .
Furthermore, this mode of stimulation seemed to be more efficient than exogenous addition of IL-2. In order to demonstrate this effect, IL-2-loaded aAPCs (s/o/w trehalose-high) were compared with unloaded aAPCs in the presence and absence of equal concentrations of exogenous, titrated rhIL-2 (5 ng/ml at highest concentration). While the addition of exogenous rhIL-2 produced a moderate increase in IFN-γ secretion, paracrine delivery of rhIL-2 more than doubled this response (Figure 5c ). In order to determine whether this effect is caused by the burst of cytokine from the particle observed at early time points or by sustained release over time, the particles were allowed to release rhIL-2 at 37 °C for 7 days, and were then washed and coupled to antibodies before T-cell stimulation. As shown in Figure 5d , cells exhibited only moderate decreases in IFN-γ secretion even when the burst release of cytokine was washed away before T-cell stimulation. This supports the hypothesis that gradual release of cytokine from the aAPC during the stimulation period has significant effects on the magnitude of stimulation.
Next, we compared the performance of this system with soluble antibodies and a commercially available aAPC platform, 4 µm Dynal beads (at equivalent particle concentrations) loaded with anti-CD3 and anti-CD28, in the presence of exogenous rhIL-2 (Figure 5e ). Soluble antibody and Dynal beads induced lower IFN-γ secretion than both loaded and exogenous rhIL-2 aAPCs, and appeared to require higher concentrations in order to achieve peak stimulation. Reported values for the optimal stimulation of T cells with Dynal beads suggest that a 3:1 ratio of beads to cells is ideal. 41 In our study, optimal stimulation with loaded IL-2 aAPCs was achieved with a 1:64 (aAPC:T-cell ratio) for polyclonal expansion (Figure 5c and d) .
For t-cell expansion, paracrine delivery of rhIl-2 from aAPcs is more efficient than exogenous addition In order to examine the effect of paracrine rhIL-2 delivery on T-cell expansion, carboxyfluorescein diacetate succinimidyl ester (CFSE) dye-labeled B6 splenocytes were monitored during polyclonal stimulation. Only loaded IL-2 aAPCs produced nearcomplete division of T cells after 4 days of culture (Figure 6a) . Soluble antibodies and unloaded aAPCs were not as efficient in facilitating T-cell division even with a tenfold increase in the level of exogenous rhIL-2. In addition, we observed significant improvements in the absolute number of cells expanded with IL-2 loaded aAPCs. After 1 week of culture without restimulation, B6 splenocytes showed a 45-fold expansion in absolute cell numbers in comparison with other methods for stimulation (Figure 6b) .
Polyclonal expansion of T cells by aAPCs led to an increase in the proportion of CD8 + T cells. The addition of exogenous rhIL-2 to cultures containing unloaded aAPCs did not produce CD8 + CFSE Low populations equal to those of loaded IL-2 aAPCs (Figure 6c) . Increasing the concentration of exogenous rhIL-2 improved stimulation, but expansion remained less than in cells treated with loaded IL-2 aAPCs. Only an increase in the concentrations of soluble antibody and rhIL-2 by an order of magnitude produced effects comparable with those produced by loaded IL-2 aAPCs (Figure 6d) . Analogous results were observed with antigen-specific stimulation, with the percentage The effect of delivering rhIL-2 from microparticle artificial antigen-presenting cells (aAPCs) was investigated by stimulating B6 splenocytes (5 × 10 5 cell/ml) for 60 hours at 37 °C. aAPCs presenting anti-CD3 and anti-CD28 with varying IL-2 loads (depending upon the method of encapsulation) were titrated in order to determine the optimal concentration for stimulating interferon-γ (IFN-γ) production by B6 splenocytes. The concentration of aAPCs for which peak IFN-γ secretion occurs is shown for each formulation. (c) The stimulation of B6 splenocytes by aAPCs with encapsulated IL-2 (triangles) was compared with the corresponding stimulative effects of aAPCs with exogenous addition of the cytokine (squares), and aAPCs without IL-2 (circles). The titration of all groups began at 5 mg/ml of microparticles (antibody concentration of 5 μg/ml). (d) Splenocytes were stimulated by aAPCs displaying anti-CD3 and anti-CD28. The aAPCs were either freshly prepared (squares) or allowed to release cytokine in phosphate-buffered saline (PBS) at 37 °C for 7 days and then washed before the antibodies were loaded (triangles). aAPcs increase the sensitivity of t cells to Il-2 and selectively expand cd8 + cells CD25, the α-chain of the IL-2 receptor, is an established activation marker that is upregulated when in vitro T-cell stimulation occurs. 42 It was found that the expression of CD25 increased with each of the stimulation methods, but was even further upregulated on cells that had been exposed to loaded IL-2 aAPCs (Figure 7a) . In addition, subset T-cell analysis revealed that loaded IL-2 aAPCs preferentially expanded CD8 + T cells with near 100% selectivity during polyclonal expansion (Figure 7b ). This is in contrast to the results obtained from other methods of stimulation investigated in this work, including commercially available magnetic beads. Unloaded aAPCs with and without rhIL-2 produced near-equal proportions of CD4 + and CD8 + T cells, whereas soluble antibodies and Dynal beads (used at a 3:1 ratio of beads:cells), in the presence or absence of exogenous rhIL-2, selectively expanded CD4 + T cells. These results are in agreement with findings from earlier studies, demonstrating that some aAPC platforms, both cellular and acellular, preferentially expand CD4 + T cells. 9, 43 T cells that are expanded with loaded IL-2 aAPCs are functional and activated, as inferred from the upregulation of the activation markers CD25, CD44, and CD69 (Figure 7c ).
dIscussIon
The novel system presented in this study embodies several key features of an ideal aAPC for use in adoptive immunotherapy. First, the ideal aAPC should be easily modifiable to accommodate a variety of ligands. Second, it would be desirable for this ideal aAPC to release cytokines in a tunable manner at the site of interactions with T lymphocytes. While exogenous addition of a cytokine is a simple strategy to augment signaling in vitro, we have demonstrated that paracrine signaling through aAPCs, made possible by the degradable nature of our aAPCs, is a much more effective strategy, because it enhances expansion at a lower concentration of potentially toxic cytokines, and selectively expands b 45- CD8 + T cells. Third, the ideal system should enable stable storage and ensure safety in the event of accidental injection.
Professional APCs such as dendritic cells can be viewed as micron-sized biological objects assembled from nano-scale units, which are highly optimized for interaction with T cells. Biodegradable polymer particulates, as described in this report, are well suited for the design of an aAPC that is both easily generalized and highly optimized, possessing the essential features of professional cellular aAPCs with additional attractive properties such as: (i) control over the size-range of fabrication, from tens of microns down to 100 nm or lower; (ii) reproducible biodegradability without the addition of enzymes or cofactors; 44 (iii) capability for sustained release of encapsulated, protected cytokine factors that may be tuned from days to months by varying preparation conditions or factors such as the PLA:PGA copolymer ratio; 45 (iv) well-understood fabrication methodologies offering flexibility in respect of many parameters, including choice of polymer, solvent, stabilizer, and scale of production; and (v) control over the introduction and sustained presentation of modular functionalities onto the aAPC surface. 29 The system described in this work highlights a new finding regarding the value of paracrine cytokine delivery for T-cell stimulation and expansion. The increased potency of rhIL-2 delivered in a paracrine, sustained manner allows the use of smaller amounts of cytokine to achieve greater T-cell activation and expansion as compared to exogenous cytokine addition. This increased responsiveness of T cells to controlled rhIL-2 release from aAPCs could be the result of two possible mechanisms.
In the first of these possible mechanisms, the released IL-2 associates with the particle surface nonspecifically, presenting the cytokine in a manner that enhances its activity: a conversion of the IL-2 to a "superagonist" similar to what has been shown by Sprent and colleagues using antibodies to IL-2. 46 The second possible mechanism is based upon the simple fact that proximity of presentation results in better capture of released IL-2, thereby facilitating enhanced T-cell responsiveness. 47 In order to distinguish between these mechanisms, we note that particles incubated with exogenous rhIL-2 do not stimulate as effectively as rhIL-2 that is released from within (Figures 5c and 6a-f) . In addition, particles from which excess IL-2 (that may be associated with the surface) have been thoroughly washed away are only slightly less effective than unwashed particles (Figure 5d ). These observations argue against the "superagonist" mechanism and suggest a proximity effect model wherein the sustained release of rhIL-2 by aAPCs in proximity to T cells increases its local concentration and sensitizes the cells to the presence of IL-2 through upregulation of CD25. This process is demonstrated in Figure 7a . A schematic of this proposed mechanism is depicted in Figure 8 . Stimulation of T cells in this manner results in selective expansion of the CD8 + T-cell subset (Figure 7b ). This offers distinct advantages with regard to efficiency and time, as no separation step is required to enrich for CD8 + cells.
A practical advantage of the acellular aAPC described here is its potential for long-term storage and transportation without loss of integrity. We have found that assembled aAPCs retain their stimulatory capacity for at least 1 week when stored at 4 °C (Supplementary Figure S5) . This, combined with the tunability of the platform, ensures the potential for widespread use in a number of therapeutic and investigative application-specific configurations.
MAterIAls And Methods
Cell lines and primary cells. Animal studies were approved by the Institutional Animal Care and Use Committee at Yale University (New Haven, CT). All animals were routinely used at 6-8 weeks of age, were maintained under specific pathogen-free conditions, and were routinely checked by personnel from the Yale University Animal Resource Center. C57BL/6 (B6) mice were obtained from Jackson Laboratories (Bar Harbor, ME). OT-I TCR transgenic breeder mice were a generous gift from Ruslan Medzhitov (Yale University) and were bred heterozygously on a B6 background in our animal facility. Phenotypes were screened using V-α2 and CD8α antibodies (eBioscience, San Diego, CA). B3Z hybridoma cells with Both micro-and nanoparticles were surface-modified with avidinpalmitate conjugate as described previously. 29 For cytokine encapsulation, 100 µg of rhIL-2 (obtained as a generous gift from Maria Parkhurst, National Cancer Institute) was lyophilized with or without a tenfold excess by mass of trehalose (Sigma Aldrich, St. Louis, MO), and incorporated as a solid during fabrication (s/o/w single emulsion technique) or added in 100 µl of PBS (water-in-oil-in-water emulsion technique) without trehalose. The particles were lyophilized and stored at −20 °C until use.
Characterization of biodegradable aAPCs. The particles were imaged using scanning electron microscopy. Images were analyzed with NIH ImageJ to determine the size distribution of particle diameters by counting at least 150 particles/sample. For loaded IL-2 aAPCs, a controlled release profile was obtained in 1 ml PBS at 37 °C from 10 mg of particles. Enzymelinked immunosorbent assay analysis was performed to measure rhIL-2 levels (BD Biosciences, San Jose, CA). The density of avidin on the particle surface was determined using the micro bicinchoninic acid assay (Pierce, Rockford, IL) in accordance with the manufacturer's instructions, with the exception that particles were removed by centrifugation before absorbance readings were performed. Ligand coupling to the particle surface. Biotinylated anti-mouse CD3ε (BD Biosciences, San Jose, CA) or biotinylated peptide-loaded MHC-K b -Ig dimers (obtained as a generous gift from Jonathan Schneck, Johns Hopkins University) 48 and anti-mouse CD28 (BD Biosciences, San Jose, CA) were added at 10 µg/ml to a 10 mg/ml solution of PLGA particles in PBS and rotated at room temperature for 20 minutes. Particles were washed with PBS + 1% fetal bovine serum and resuspended in complete RPMI-10 medium. Anti-CD28, when present, was added at a 1:1 molar ratio to anti-CD3 or MHC-K b -Ig.
T-cell stimulation studies. aAPCs coated with antibody or MHC were titrated across rows of a round-bottom 96-well plate (BD Biosciences, San Jose, CA) in 100 µl of media per well. Equal masses of micro-and nanoparticles were used, beginning with a maximum concentration of 5 mg/ml. B6 splenocytes or OT-I CD8 + T cells were added to each well at a final concentration of 5 × 10 5 cells/ml (B6) or 1 × 10 5 (OT-I). Nonbiodegradable Dynal beads (4 µm diameter; Invitrogen, Carlsbad, CA) were used at a concentration of beads equal to the PLGA microparticle concentrations (1 × 10 5 microparticles/mg of polymer). In all cases, the highest concentration of aAPCs or beads corresponded to a 1:1 ratio of cells:particles, and the highest antibody concentration was 5 µg/ml. After incubation at 37 °C for 60 hours, plates were centrifuged at 1,500 rpm for 7 minutes in a table top centrifuge, and the supernatant was removed for IFN-γ enzyme-linked immunosorbent assay analysis or mIL-2 enzyme-linked immunosorbent assay. Cell pellets were resuspended in media and analyzed for viability using Cell Titer Blue (Promega, Madison, WI). For burst release studies, aAPCs were allowed to release IL-2 in PBS at 37 °C for 7 days prior to coupling to biotinylated anti-CD3 and anti-CD28 and use in stimulation studies. For stability studies, assembled aAPCs were incubated at 4 °C for 1 week before use. The values reported were obtained by using dilutions of supernatant that yielded absorbance values within the linear portion of the standard curve.
Fluorescence microscopy. B3Z cells were washed twice in PBS to remove serum proteins before being incubated with poly-l-lysine-coated cover slips (BD Biosciences, San Jose, CA). 1 × 10 6 cells/ml were added in serumfree RPMI-1640 at 37 °C for 1 hour. The cover slips were then blocked in RPMI-10 medium for 10 minutes at room temperature. aAPCs with encapsulated Rhodamine B (Acros Organics, Geel, Belgium) and attached anti-CD3 and anti-CD28 were added to cover slips at 5 mg/ml in RPMI-10. Following a 1-hour incubation at 4 °C, cover slips were washed and fixed with 4% paraformaldehyde (USB, Cleveland, OH) for 10 minutes at room temperature. After fixing, the cells were permeabilized and stained with phalloidin-fluorescein isothiocyanate (Invitrogen, Carlsbad, CA) and Vectashield with 4′,6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA). Slides were visualized using a Leica SP5 confocal microscope (Leica Microsystems, Bannockburn, IL).
Assessment of expansion by flow cytometry. CFSE-labeled B6 splenocytes or OT-I CD8 + T cells (2 × 10
6 cells) were exposed to various concentrations of soluble ligands (anti-CD3 for polyclonal stimulation, and SIIN K b dimers for antigen-specific stimulation (anti-CD28 was present in both cases at a 1:1 molar ratio), or ligand-coated aAPCs in the presence or absence of rhIL-2 and trehalose. Antibodies and rhIL-2 were added to achieve the indicated final concentrations in 2 ml of media. aAPCs were added at 0.3 mg/ml final concentration (40:1 cells:aAPCs). Dynal beads were used at a 3:1 ratio of beads:cells with concentrations of antibody equal to those of aAPCs. All antibodies, aAPCs, rhIL-2, and trehalose were added at the beginning of the experiment with no restimulation during the course of the study. Cell aliquots were obtained on day 4, and flow cytometric analysis was performed using a Becton Dickenson FACScan instrument (San Jose, CA) and FlowJo software (Tree Star, Ashland, OR). Splenocytes were stained with a 1:200 dilution of anti-CD8 phycoerythrin and OT-I CD8 + T cells were stained with a 1:20 dilution of phycoerythrin-labeled SIIN K b tetramer (Beckman Coulter, Fullerton, CA). Analysis of fluorescence was performed after gating on the lymphocyte population in side scatter versus forward scatter plots, and, where noted, the CD8 + subset. Staining for activation markers was performed using anti-CD25, anti-CD44, and anti-CD69, all phycoerythrinlabeled, and subset analysis was carried out using anti-CD4 fluorescein isothiocyanate and anti-CD8 phycoerythrin. All antibodies were obtained from BD Biosciences (San Jose, CA). In order to measure absolute cellular expansion of splenocyte cultures, the cells were analyzed on a Multisizer3 (Beckman Coulter, Fullerton, CA) at dilutions within the working range of the instrument. Particle counts were independently measured and subtracted from samples undergoing aAPC stimulation.
Data fitting and statistical analysis. Data fitting was performed using GraphPad Prism 4.0 (GraphPad Software, San Diego, CA). Controlled release data were fitted to a two-phase exponential association model, and stimulation data were fitted to a receptor cross-linking model 33 where the equation of fit is given by C is the independent variable, concentration of ligand, C max is the ligand concentration at which a maximal response is observed, and P 1 and P 2 are parameters relating to the height and width of the curve. Response where 1 ( )
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